The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) hit a new 52-week low and has $31.47 target or 6.00% below today’s $33.48 share price. The 5 months bearish chart indicates high risk for the $2.90B company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $31.47 price target is reached, the company will be worth $174.00 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 1.39 million shares traded hands. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 44.51% since April 1, 2016 and is downtrending. It has underperformed by 45.73% the S&P500.
Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on November, 14. They expect $-1.20 earnings per share, down 31.87% or $0.29 from last year’s $-0.91 per share. After $-1.05 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage
Out of 14 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 8 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 57% are positive. Alnylam Pharmaceuticals has been the topic of 29 analyst reports since August 7, 2015 according to StockzIntelligence Inc. On Monday, August 31 the stock rating was maintained by Piper Jaffray with “Overweight”. Morgan Stanley initiated Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Tuesday, August 2 with “Overweight” rating. The rating was maintained by FBR Capital on Thursday, October 6 with “Outperform”. JMP Securities maintained it with “Outperform” rating and $144 target price in Friday, August 28 report. The firm has “Neutral” rating given on Thursday, September 29 by Janney Capital. The rating was downgraded by JP Morgan on Thursday, October 6 to “Neutral”. On Friday, August 7 the stock rating was downgraded by JP Morgan to “Neutral”. As per Tuesday, May 3, the company rating was maintained by Leerink Swann. The firm earned “Hold” rating on Saturday, August 22 by TheStreet. The rating was upgraded by JP Morgan to “Overweight” on Friday, March 11.
According to Zacks Investment Research, “Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.”
Insitutional Activity: The institutional sentiment decreased to 1.27 in 2016 Q2. Its down 0.21, from 1.48 in 2016Q1. The ratio is negative, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
Amp Cap Investors Limited accumulated 19,559 shares or 0.01% of the stock. Fortaleza Asset Management has 35 shares for 0% of their US portfolio. Turner Invs L P accumulated 0.18% or 10,370 shares. American Century has 10,393 shares for 0% of their US portfolio. Northern Trust, a Illinois-based fund reported 364,375 shares. Moreover, Kidder Stephen W has 0.17% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 7,525 shares. Aviva Public Limited Company has 44,126 shares for 0.02% of their US portfolio. Commonwealth Financial Bank Of owns 300 shares or 0% of their US portfolio. Rockefeller Financial Incorporated reported 5,302 shares or 0.01% of all its holdings. Morgan Stanley holds 875,104 shares or 0.02% of its portfolio. First Manhattan Communication holds 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 2,000 shares. Blackrock Limited Liability Com has invested 0.02% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Advisory Svcs Network has 10 shares for 0% of their US portfolio. Altrinsic Global Llc reported 72,700 shares or 0.11% of all its holdings. Baillie Gifford & Com accumulated 3.39M shares or 0.34% of the stock.
Insider Transactions: Since July 19, 2016, the stock had 1 buying transaction, and 1 sale for $918,262 net activity. The insider PYOTT DAVID E I bought 27,900 shares worth $1.03 million. MARAGANORE JOHN sold $1.95 million worth of stock or 30,151 shares.
More important recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “What’s Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure?” on October 07, 2016, also Fool.com published article titled: “Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.”, Wsj.com published: “Alnylam Says Trial of Patisiran Can Continue Following Revusiran Halt” on October 10, 2016. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was released by: Prnewswire.com and their article: “Lifshitz & Miller Law Firm Announces Investigation of Alnylam Pharmaceuticals …” with publication date: October 28, 2016.
ALNY Company Profile
Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.